anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants assigned to the control group, will not complete the experimental dental anxiety management program at this time. They will complete study paperwork and watch a non-dental video for 45 minutes before their scheduled dental appointment. Immediately after the dental appointment, they will complete a brief interview with the research staff person.
A family of products designed to ameliorate sinusitis and allergic rhinitis, produced by combining certain chemical substances with existing products, thereby producing a synergistic effect and relief. The chemical substances create an electrostati-cally charged field around the nose and prevent allergens or pollutants from entering the nostrils to cause a reaction, illness, or discomfort for the user. Therefore, the Present Invention comprises products, which are applied to the face, and therefore around the nose and nasal passages, as well as those applied directly into the nose.  These products include but are not limited to nasal sprays, rinses, washes, sunscreens, nasal strips, swabs (medicated and non-medicated), tissues, towelettes, cosmetics, and fra-grances.  Common nasal sprays often comprise saline solutions. Cosmetics comprise camouflage paint or theatrical makeup. The principle function of the Present Invention is to prevent harmful airborne particulates from entering the nose when either sprayed into the nose or applied to the face, nose, or nasal passages.
The invention relates to a compound for synergistically resisting dental plaque and inhibiting dental ulcer and an application method of the compound in mouthwash, chewing gum and toothpaste, and belongs to the field of oral hygiene. The compound comprises indigo, indirubin and inorganic fluoride salt. The raw materials for applying the compound to the mouthwash comprise indigo, indirubin, inorganic fluoride salt, surfactant, sweetener, spice, preservative and deionized water. The preparation method comprises the following steps: sequentially putting inorganic fluoride salt, indigo, indirubin and other auxiliary materials into deionized water, stirring for 20-35min by using vacuum high-speed shearing equipment, and obtaining the mouthwash after the mouthwash is clear and free of precipitates. The compound of the invention has the functions of resisting infection and enhancing immunity, and has the functions of resisting dental plaque and inhibiting dental ulcer. The compound of the invention can be applied to mouth wash, chewing gum and toothpaste.
Long covid (persistent COVID-19) is a new disease with contested aetiology and variable prognosis. We report a 2-year ethnography of UK long covid clinics. Using a preformative lens, we show that multidisciplinary teams (MDTs) built working knowledge based on shared practices, mutual trust, distributed cognition (e.g. emails, record entries), relational knowledge of what was at stake for the patient, and harnessing uncertainty to open new discursive spaces. Most long covid MDTs performed the working knowledge of 'rehabilitation', a linked set of practices oriented to ensuring that the patient understood and strove to 'correct' maladaptive physiological responses (e.g. through breathing exercises) and pursued recovery goals, supported by physiotherapists, psychologists and generalist clinicians. Some MDTs with a higher proportion of doctors (e.g. cardiologists, neurologists, immunologists) enacted the working knowledge of 'microscopic damage', seeking to elucidate and rectify long covid's underlying molecular and cellular pathology. They justified non-standard investigations and medication in selected patients by co-constructing an evidentiary narrative based on biological mechanisms. Working knowledge was ontologically concordant within MDTs but sometimes discordant between MDTs. Overt ontological conflict occurred mostly when patients attending 'rehabilitation' clinics invoked the working knowledge of microscopic damage that had been generated and circulated in online support communities.
Participants randomised to the control group will receive a health consultation from a trained researcher once a week for 4 weeks. The health consultation will be tailored to the participants' needs. Based on a previous study, the health consultation will include pain management, healthy nutrition, how to make best use of medical services and education and counselling for individual health-related concerns.
AIMS: To explore the effectiveness of the Taiwanese Diabetes Shared Care Program (DSCP) on improving the metabolic indicators of people with type 2 diabetes.
METHODS: Relevant studies published between January 2002 and August 2021 were retrieved from Chinese- and English-language electronic databases, including PubMed, MEDLINE, CINAHL, ProQuest, Cochrane Library, Airiti Library, and Taiwan Periodical Literature System. After screening, studies that met inclusion criteria were included in the literature review. RevMan 5.4 was employed for a meta-analysis.
RESULTS: Ten studies published between 2007 and 2021 were included in the systematic review, with nine of them contributing to the meta-analysis. In total, 1506 and 1388 participants were classified into DSCP and non-DSCP groups, respectively, for the meta-analysis. The results revealed that the DSCP significantly improved glycated hemoglobin levels (mean difference [MD]: -0.50, 95% Confidence Interval [CI]: -0.83 to -0.17) and body weights (MD: -0.83, 95% CI: -1.29 to -0.38) within 1-year follow-up. However, it did not show significant improvement in other metabolic indicators.
CONCLUSIONS: Taiwanese DSCP led to improvements in glycated hemoglobin levels and body weights among people with type 2 diabetes. This study suggests that people with diabetes and health-care institutions should consider participating in the DSCP.
Patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15; lapatinib ditosylate PO QD on days 1-21 or on days 1-3, 8-10, and 15-17; and trastuzumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Ovarian cancer (OC) remains the most lethal gynecologic malignancy owing to late detection, intrinsic and acquired chemo-resistance and remarkable heterogeneity. There is an unmet medical need to develop new therapy modalities. In preclinical studies, GL-ONC1, has shown the ability to preferentially locate, colonize and destroy tumor cells in more than 30 different human tumors, including ovarian cancer. GL-ONC1 has been investigated in early stage clinical trials in the United States and Europe via systemic delivery as monotherapy and in combination with other therapies, and via regional delivery as monotherapy. GL-ONC1 treatment was well tolerated across different malignancies, routes of administration, and monotherapy as well as combination therapy protocols. The ability of GL-ONC1 to infect tumor tissue and kill tumor cells was demonstrated. In addition, virus-induced immune activation and favorable anti-tumor immune response have been observed. Evidences of anti-tumor efficacy and clinical benefits have also been documented.
Sixteen stroke patient receiving a conventional PT and OT program and sham tDCS for 5 consecutive days per week for a 3 week period ( a total of 15 sessions). The one hour long conventional PT and OT sessions will be the same as in the tDCS group. For sham tDCS, electrode application and positioning will be the same as the intervention group and will be applied at the beginning of each OT session as previously described. The current will initially be increased up to 2 mA, so to provide the typical initial tingling sensation, and slowly decreased over 30 seconds and consequently switched off. The electrodes will be removed after a total of thirty minutes.
Famotidine will be administered at total daily doses of 80, 120mg, or 160mg per day. Each patient will be randomized to receive each active dose of famotidine (80, 120, or 160mg/d and placebo). Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo.
Carcinogenicity studies have not been conducted with olaparib.

Olaparib was clastogenic in an in vitro chromosomal aberration assay in mammalian Chinese hamster ovary (CHO) cells and in an in vivo rat bone marrow micronucleus assay. This clastogenicity is consistent with genomic instability resulting from the primary pharmacology of olaparib and indicates potential for genotoxicity in humans. Olaparib was not mutagenic in a bacterial reverse mutation (Ames) test.

In a fertility study, female rats received oral olaparib at doses of 0.05, 0.5, and 15 mg/kg/day for at least 14 days before mating through the first week of pregnancy. There were no adverse effects on mating and fertility rates at doses up to 15 mg/kg/day (maternal systemic exposures approximately 7% of the human exposure (AUC0-24h) at the recommended dose).

In a male fertility study, olaparib had no effect on mating and fertility in rats at oral doses up to 40 mg/kg/day following at least 70 days of olaparib treatment (with systemic exposures of approximately 5% of the human exposure (AUC0-24h) at the recommended dose).
PURPOSE:To obtain an adsorbent having high metal adsorptivity which can adsorb ions from liquid of rather low pH by substituting carboxymethyl groups for hydrogen of aimino groups in chitosan. CONSTITUTION:The chitosan is obtained by heating chitin contained in shells of Crustacea such as lobster, crab in an alkali soln. Chemically modified units expressed by formula I (n=1 or 2) in which carboxymethyl groups are substituted for hydrogen in the amino group of chitosan are formed in the polymer skeleton of the chitosan. By forming carboxymethyl groups, pKa changes so that the obtd. material has higher coupling ability with metal ions than chitosan itself and can act in a soln. of lower pH than compared to chitosan. The obtd. adsorbent is a low-cost one since the starting material is obtd. from biomass waste, and has high metal adsorptivity which can act even in a low pH soln.
he invention relates to a method of transferring frequencies containing various crystals to substances such as water, polar dyalizers, creams and binding substances used for the production of cosmetics and pharmaceutical preparations containing same frequencies. The innovation of the invention consists in the use of crystals employed as resonance material and frequencies filter and in the transfer and registering of frequencies on substrates such as water. The perfect geometrical nature of thecrystal guaranties the stability of the information transferred to the substrates chiefly to water. In this manner, the introduction of frequencies into the human organism is not carried out by means of electrodes but by direct introduction of the precise substrate (water) in the human organism. Through the herein described method, the invention allows the production of water carrying information about basic homeopathetical substances so that a novel more liable homeopathy is created. Said frequencies transferred, for instance, by means of water to the human organism have a direct impact to the brain imposing a functional frequency by replacement of the pathological frequency of the body and limbs system/cerebral cortex.
A wireless microphone communication system 1 comprises a transmitter 91b of a wireless microphone and a receiver 11 for the wireless microphone. The transmitter 91b of the wireless microphone includes an infrared interface 91c, a control portion 91d, and a function control portion 91e that controls a function of the wireless microphone. The control portion 91d controls the function control portion 91e according to information transmitted through the infrared interface 91c. The function of the transmitter 91b of the wireless microphone is controlled under this control. The receiver 11 of the wireless microphone has the infrared interface 11c. The receiver 11 of the wireless microphone sends, through the infrared interface 11c, information in the form of the infrared signal to control the function of the transmitter 91c of the wireless microphone.
A recombinant expression system for the expression of a poly amino acid, peptide or protein is provided. The poly amino acid of interest is expressed as a fusion protein that includes an amino acid sequence recognized and cleaved by a Ulp1 protease. The amino acid sequence joined to the poly amino acid of interest is preferably from a SUMO (small ubiquitin-like molecule) protein. This sequence imparts favorable solubility and refolding properties to the fusion protein. A purification tag may also be incorporated into the fusion protein for ease of isolation. The Ulp1 protease used to cleave the fusion protein may be the Ulp1 protease or the active Ulp1 protease fragment, Ulp1 (403-621). The Ulp1 protease rapidly and specifically cleaves the fusion proteins of the invention at the Ulp1 cleavage site. The amino acid sequence recognized by a Ulp1 protease is cleaved asymetrically to leave only an N-terminal serine joined to the poly amino acid of interest. This recombinant expression system is particularly advantagious for expression and rapid and highly specific cleavage and purification of poly amino acids that have low solubilities or are difficult to express in other systems.
Subjects in Arm 2 will be observed from initiation of conditioning to Day +14. If subjects develop G1 or G2 OM via WHO OM scale during this period, they will at that time be randomized to immediately receive GEL.
The present invention provides Pre-term Placenta Extra-embryonic Tissue Cell (PPETC) populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of using such cells for therapeutic and diagnostic applications. The present invention provides a method for isolation of extra-embryonic cell population will which are to be obtained preferably from premature discarded placenta by a process of non-enzymatic digestion or mechanical disruption. The isolated cells are cultured in semi-solid glycosaminoglycan-based three-dimensional milieu supplemented with autologous umbilical cord-derived serum. The isolated cells which are expanded in semi-solid media will be formulated for intravenous injections to patients having end stage cystic fibrosis. A preferred method of formulating cells for intravenous injection and optimal cell number are described herein. The PPETC may also used to diagnose diseased organs and elicit a robust immune response to stem cell markers commonly found in certain type of cancer stem cells.
Cloperastine (CLP) is a drug with a central antitussive effect that is used to treat bronchitis. Therefore, we have attempted to examine the anti-inflammatory effects of CLP. CLP reduced the secretion of interleukin (IL)-6, a pro-inflammatory cytokine, from RAW264.7 monocyte/macrophage-linage cells treated with lipopolysaccharide (LPS). IL-6 is a biomarker of sepsis and has been suggested to exacerbate its symptoms. We found that the intraperitoneal administration of CLP reduced IL-6 levels in the lungs and also improved hypothermia in mice with LPS-induced sepsis. CLP ameliorated kidney pathologies such as congestion and increased the survival rate of mice administered with a lethal dose of LPS. To reveal the mechanisms underlying the anti-inflammatory function of CLP, we analysed the intracellular signaling in LPS-treated RAW264.7 cells. CLP induced the phosphorylation of protein kinase B (Akt) and glycogen synthase kinase 3 (GSK3) and also increased the amount of nuclear factor erythroid-2-related factor 2 (Nrf2) in RAW264.7 cells with/without LPS. Wortmannin, an inhibitor of phosphoinositide 3-kinase (PI3K), reduced the upregulated phosphorylation levels of Akt and GSK3 and the increased amount of Nrf2. It also halted the reduction of IL-6 secretion caused by CLP. These results suggest that CLP has an anti-inflammatory function via Akt/GSK3/Nrf2 signaling and could be a candidate drug for the treatment of inflammatory diseases, including sepsis.
NEW MATERIAL:A compound shown by the formula I (A is lower alkylene; RCO is acryl; broken line is single or double bond). EXAMPLE:16beta-Ethyl-17beta-n-hexanoyloxyacetoxy-4-estren-3-one. USE:An agent for alleviating male hormone or a remedy for prostatic hypertrophy. Having low toxocity, capable of being medicated orally. PREPARATION:1mol compound shown by the formula II is reacted with preferably 1-3mol salt of a carboxylic acid shown by the formula RCOOH in a solvent usually such as water, acetone, etc. at -30-120 deg.C for 10-30hr.
Patients in the group were treated with both targeted therapy and microwave ablation. Patients were treated with Almonertinib with the dose of 110mg once daily firstly. When the best response achieved, microwave ablation was conducted in the primary tumors, and then followed by Almonertinib treatments.
It consists of implementing active breaks at the workstation through the use of the open source Learning Management System Sakai \[33\], It will be easy to use by the participants due to the platform is used by them in their daily work. Also, an administrative worker from the university will be involved in creating the modules where the content will be allocated to ensure that the navigation in the platform is user-friendly for them.musculoskeletal pathologies with sedentary lifestyles and maintained postures. The type of online application will depend on the results obtained in the qualitative phase, as we will adapt to the workers' preferences to facilitate accessibility to the content and make the experience as satisfactory as possible for them.
Patients receive carboplatin IV over 30 minutes on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Do not start desvenlafaxine extended-release tablets in a patient who is being treated with linezolid or intravenous methylene blue because there is increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered [see CONTRAINDICATIONS (4)].

In some cases, a patient already receiving desvenlafaxine extended-release tablets therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, desvenlafaxine extended-release tablets should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for 7 days or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with desvenlafaxine extended-release tablets may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue [see WARNINGS AND PRECAUTIONS (5.2)].

The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with desvenlafaxine extended-release tablet is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with such use [see WARNINGS AND PRECAUTIONS (5.2)].
The present invention is directed to novel hexanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, particularly in the treatment of type 2 diabetes and conditions that are associated with the same. In addition, the present invention provides pharmaceutical compositions useful in inhibiting DPP-IV enzyme, comprising a therapeutically effective amount of hexanoic acid derivatives. Moreover, the present invention provides a method of inhibiting DPP-IV comprising administering to a mammal in need of such treatment a therapeutically effective amount of a single or a combination of hexanoic acid derivatives of the invention. The invention further relates to the kits and other articles of manufacture for treating disease states associated with DPP-IV enzyme. The invention further relates to a method of identifying a compound that has dipeptidyl peptidase-IV enzyme inhibition activity, comprising following steps: 1. Define the residues of the active site of DPP-IV 2. Define the geometry and force field relationship of the residues identified above in (I) 3. Define the physical parameters of the active site identified in (1) 4. Validate the model based on mutational analysis and in-vitro inhibitor binding studies 5. Screen the library for scaffolds and small molecules that satisfy the model developed in (3) and validated in (4) above. 6. Dock each inhibitor identified in (5) above to the active site of DPP-IV defined in (1). 7. Minimize the energy of the inhibitor and DPP-IV complex using force fields used in (2) above. 8. Compare the energy of interaction of each inhibitor to that of known inhibitors. 9. Synthesize and validate in in-vitro assays
Transdermal absorption dosage units have been developed for treatment of postmenopausal syndrome which comprise a backing layer, an adjoining adhesive polymer layer in which at least minimum effective daily doses of an estrogen is microdispersed. Presently preferred is use of the natural estrogen, 17-beta-estradiol, or ethinyl estradiol or combinations thereof together with an amount of a natural progestogen or a progestin to minimize any potential side effects. The units use bioacceptable adhesive and polymers. An additional polymer layer in intimate contact with the estrogen-containing layer can be used. Also, a separating layer can optionally be used in making the dosage units, which separate the two adhesive polymer layers, which permits estrogen transmission from the first adhesive polymer layer during treatment. Dosage units are provided which transdermally deliver at least minimum daily doses of the estrogen for at least one day or for multiple days, such as for one week. The invention also provides a process for postmenopausal syndrome treatment using the novel dosage units.